Announcing: ZXEREX Safe™ screening for Marijuana impairment for the workplace

Impairment due to drugs, fatigue, and stress are contributing to the $171B USD cost of injuries in the workplace

SCOTTSDALE, ARIZONA, USA, January 18, 2022 /EINPresswire.com/ -- Growing use of medicinal and recreational marijuana is causing concern about rising workplace injuries, absenteeism, and losses of productivity. In addition to marijuana impairment, opioid abuse is on the rise. According to the National Safety Council (NSC), “impairment is often a hidden risk that prevents someone from being at their best and able to perform safely. On the roadway and at work, impairment can kill. Impairment negatively affects safety in both seen and unseen ways, including impacting the business bottom line.” The NSC recommends that companies adopt safety programs and policies that address impairment risk due to drug abuse, fatigue, and stress. In 2019, workplace impairment contributed to the $171B USD injury costs including wages, productivity losses, medical and administrative expenses, and uninsured costs.

ZXEREX Corporation is announcing ZXEREX Safe™, a revolutionary science-based approach to impairment screening that will discourage employees from showing up impaired or using drugs on the job. The early identification of impairment risk benefits all employees, co-workers, the company, and its customers. When combined with the company’s in-house risk-management and safety program, ZXEREX Safe™ will help risk and safety managers to mitigate the effects of workplace impairment. This is a proactive approach will help to deter employees from showing up impaired and unable to safely perform jobs, such as driving, operating machinery, operating heavy equipment, using of sharp objects, and even among those with direct customer contact.

ZXEREX is a biotechnology company that was formed to help employers better manage workplace impairment. Its team including a physician, two Nobel-laureate trained neuroscientists, a businessman, and an engineer created the underlying technology while at Arizona State University and Barrow Neurological Institute. Thereafter, the company conducted human studies at SUNY Downstate Medical Center to determine the effect of Marijuana on the brain’s control of voluntary and involuntary eye movements. In addition to Marijuana, ZXEREX continues to conduct studies at other well-known medical centers on opioids, fatigue, and stress, all of which contribute to workplace impairment.

It is well recognized that psychoactive drugs alter brain function and the brain’s control of eye movement. By analyzing the effect of a drug on eye movement, ZXEREX’s patented technology provides a disruptive way to address the inability of urine and saliva drug tests to determine Marijuana impairment.

Being cost effective, rapid screening using ZXEREX Safe™ can be used at the start, during, and at the end of the workday. It’s non-invasive, takes 1-2 minutes, and requires no training. The employee’s eye movements are analyzed in a cloud computer using machine learning and artificial intelligence.

Though COVID-19 is an immediate challenge for most companies, mitigating workplace impairment risk continues to be an important issue. ZXEREX-Safe™ workplace screening represents an important step in injury prevention and control of its economic impact upon the company, employees, and their families.

ZXEREX wants to help companies create safe, impairment-free workplaces while recognizing the need to respect the employee, support employee retention, and enhance recruiting.

Please visit our website to learn more about ZXEREX Safe™ and to learn how your company can participate.

For more information, visit ZXEREX CORPORATION at http://www.zxerex.com or email info@zxerex.com or call 1-480-518-9905.

Richard Besserman
ZXEREX CORPORATION
+1 480-518-9905
rb@zxerex.com